Silence Therapeutics Secures $2M Milestone Payment

Silence Therapeutics (SLN) has released an update.

Silence Therapeutics, a biotech firm specializing in RNA interference for disease treatment, has received a $2 million payment from Hansoh Pharma upon reaching a key research milestone. This payment is part of a larger collaboration that could yield Silence up to $1.3 billion in various milestones, along with royalties on product sales. The partnership, which began in October 2021, leverages Silence’s mRNAi GOLD™ platform to develop siRNAs targeting genetic diseases, marking the fourth research milestone achieved to date.

For further insights into SLN stock, check out TipRanks’ Stock Analysis page.